DDCM: A Computational Strategy for Drug Repositioning Based on Support-Vector Regression Algorithm
-
Published:2024-05-12
Issue:10
Volume:25
Page:5267
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Xu Manyi1, Li Wan1ORCID, He Jiaheng1, Wang Yahui1, Lv Junjie1, He Weiming2, Chen Lina1, Zhi Hui1ORCID
Affiliation:
1. College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150000, China 2. Institute of Opto-Electronics, Harbin Institute of Technology, Harbin 150000, China
Abstract
Computational drug-repositioning technology is an effective tool for speeding up drug development. As biological data resources continue to grow, it becomes more important to find effective methods to identify potential therapeutic drugs for diseases. The effective use of valuable data has become a more rational and efficient approach to drug repositioning. The disease–drug correlation method (DDCM) proposed in this study is a novel approach that integrates data from multiple sources and different levels to predict potential treatments for diseases, utilizing support-vector regression (SVR). The DDCM approach resulted in potential therapeutic drugs for neoplasms and cardiovascular diseases by constructing a correlation hybrid matrix containing the respective similarities of drugs and diseases, implementing the SVR algorithm to predict the correlation scores, and undergoing a randomized perturbation and stepwise screening pipeline. Some potential therapeutic drugs were predicted by this approach. The potential therapeutic ability of these drugs has been well-validated in terms of the literature, function, drug target, and survival-essential genes. The method’s feasibility was confirmed by comparing the predicted results with the classical method and conducting a co-drug analysis of the sub-branch. Our method challenges the conventional approach to studying disease–drug correlations and presents a fresh perspective for understanding the pathogenesis of diseases.
Funder
National Natural Science Foundation of China Natural Science Foundation of Heilongjiang Province, China
Reference111 articles.
1. Drug repurposing: Progress, challenges and recommendations;Pushpakom;Nat. Rev. Drug Discov.,2019 2. Monticelli, M., Liguori, L., Allocca, M., Bosso, A., Andreotti, G., Lukas, J., Monti, M.C., Morretta, E., Cubellis, M.V., and Hay Mele, B. (2022). Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones. Int. J. Mol. Sci., 23. 3. Ochoa-Maganda, V.Y., Rangel-Castañeda, I.A., Suárez-Rico, D.O., Cortés-Zárate, R., Hernández-Hernández, J.M., Pérez-Rangel, A., Chiquete-Félix, N., León-Ávila, G., González-Pozos, S., and Gaona-Bernal, J. (2020). Antigiardial Activity of Acetylsalicylic Acid Is Associated with Overexpression of HSP70 and Membrane Transporters. Pharmaceuticals, 13. 4. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide;Amare;J. Oncol. Pharm. Pract.,2021 5. Current status of drug repositioning in hematology;Ohmoto;Expert Rev. Hematol.,2021
|
|